The FDA changes the label on Johnson & Johnson's (JNJ -0.3%) Nizoral tablets to warn...

The FDA changes the label on Johnson & Johnson's (JNJ -0.3%) Nizoral tablets to warn consumers that the anti-fungal drug should not be the first line of treatment due to the risk of liver injury and adverse drug interactions. The EMA is recommending the suspension of oral treatments containing Nizoral's principal ingredient. Topical formulations of the drug have not been associated with liver damage.

From other sites
Comments (1)
  • joelgwood
    , contributor
    Comments (23) | Send Message
    This is not really significant news since Nizoral Tablets have been relegated to second or third line treatment for many years now. There are a multitude of other orally active antifungal drugs that do not use the same metabolic pathway (cytochrome p-450) and thus do not have all of the possible interactions that oral ketoconazole has.


    When Nizoral was brought to the market in 1982, it was the FIRST orally administered broad spectrum anti fungal that had been developed. It was on the United Nations list of ESSENTIAL drugs for several years until other orally administered drugs came to market. It saved many lives over the years, but do to the prolific research of the pharmaceutical industry, many more SAFER and more effective antifungals have been developed.
    26 Jul 2013, 03:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs